Cathay Fortune to Acquire Germany's Epigenomics for $186 Million

Cathay Fortune International, a Shanghai healthcare private equity firm, will acquire Berlin's Epigenomics AG for $186 million in cash. Epigenomics makes a blood plasma test that detects colorectal cancer. The Epi proColon diagnostic is marketed in the EU, the US and China. BioChain, a US company that is the largest shareholder of Epigenomics, owns China marketing rights to Epi proColon. Cathay will acquire Epigenomics through a subsidiary, Blitz F16-83. More details.... Stock Symbols: (Xetra: ECX; OTCQX: EPGNY) Share this with colleagues: // //